Progenics Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for cancer and other serious conditions. Founded in 1986, Progenics has made significant strides in the oncology sector, particularly with its pioneering work in radiopharmaceuticals and targeted therapies. The company is renowned for its flagship products, including the prostate cancer treatment, Azedra, which showcases Progenics' commitment to addressing unmet medical needs through unique therapeutic approaches. With a strong emphasis on research and development, Progenics has established a notable market position, recognised for its contributions to improving patient outcomes in oncology. As it continues to expand its portfolio, Progenics remains dedicated to advancing the field of cancer treatment and enhancing the quality of life for patients worldwide.
We don't have data for Progenics Pharmaceuticals, Inc., but we can show you information about their parent organization instead.
View parent company